Lumida
/RIGL
⌘K
Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

RIGL
$47.24USD-0.08%-0.04 today

MARKET CAP

882.4M

P/E (TTM)

12.0x

FWD P/E

15.3x

DAY RANGE

$47 – $48

52W RANGE

$25
$52

AI Summary

Stalk
StalkMedium

Despite the medium- and long-term bullish structure under a Stage 2 advance, extreme overbought conditions and an active Bullish Exhaustion pattern signal waning upside follow-through; deferred execution is advised, waiting for a pullback into the rising EMA support zone.

  • Q2 2026 net product sales $67M (+14% YoY)
  • Total Q2 revenues $78.7M; 2026 guidance $275–$290M
  • Intense oncology competition may limit market share gains
Full analysis →

Buying

4

institutions

Selling

6

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY1.94 M75.89 M+170.91 K+58.6%0.00%
JH

Janus Henderson Group Plc

Q1 2026

BUY271.75 K7.35 M+235.54 K+373.7%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL145.85 K5.71 M+-192.59 K-37.6%0.01%
AC

Aqr Capital Management LLC

Q2 2026

BUY124.80 K4.88 M+33.79 K+98.4%0.00%
MM

Millennium Management LLC

Q2 2026

SELL93.69 K3.67 M+-170.72 K-48.7%0.00%
WP

Woodline Partners LP

Q2 2026

SELL50.00 K1.96 M+-50.00 K-27.7%0.01%
JC

Jpmorgan Chase & Co

Q2 2026

BUY41.67 K1.63 M+591.00+54.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL41.70 K1.63 M+-127.40 K-64.3%0.00%
MG

Man Group Plc

Q2 2026

SELL20.80 K813.54 K+-57.23 K-61.4%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-13.07 K-100.0%0.00%